Klinická farmakologie a farmacie – 1/2018

KLINICKÁ FARMAKOLOGIE A FARMACIE / Klin Farmakol Farm 2019; 33(1): 38–42 /  www.klinickafarmakologie.cz 42 PŘEHLEDOVÉ ČLÁNKY Hypnotika v léčbě nespavosti and what we still need to learn. Sleep Med Rev 2002; 6: 97–111. 5. Ohayon MM. Observation of the natural evolution of in‑ somnia in the american general population cohort. Sleep Med Clin 2009; 4: 87–92. 6. Ellis JG, Perlis ML, Neale LF, Espie CA, Bastien CH. The na‑ tural history of insomnia: focus on prevalence and inciden‑ ce of acute insomnia. J Psychiatr Res 2012; 46: 1278–1285. 7. Pretl M. Hypnotika v léčbě nespavosti. Neurol. pro praxi 2008; 9: 160–164. 8. Morphy H, Dunn KM, Lewis M, Boardman HF, Croft PR. Epi‑ demiology of insomnia: a longitudinal study in a UK popula‑ tion. Sleep 2007; 30: 274–280. 9. Budhiraja R, Roth T, Hudgel DW, et al. Prevalence and po‑ lysomnographic correlates of insomnia comorbid with me‑ dical disorders. Sleep 2011; 34: 859–867. 10. Matheson E, Hainer BL. Insomnia: Pharmacologic Thera‑ py. Am Fam Physician 2017; 96: 29–35. 11. Bertisch SM, Herzig SJ, Winkelman JW, Buettner C. Nati‑ onal use of prescription medications for insomnia: NHANES 1999–2010. Sleep 2014; 37: 343–349. 12. Riemann D, Baglioni C, Bassetti C, et al. European guideli‑ ne for the diagnosis and treatment of insomnia. J Sleep Res. 2017; 26(6): 675–700. 13. Lie JD, Tu KN, Shen DD, Wong BM. Pharmacological Tre‑ atment of Insomnia. PT 2015; 40: 759–768. 14. Food and Drug Administration FDA drug safety com‑ munication: risk of next‑morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist) 2013. Dostupné na http://www. fda.gov/drugs/drugsafety/ucm334033.htm 15. Walsh JK, Coulouvrat C, Hajak G, et al. Nighttime insomnia symptoms and perceived health in the America Insomnia Survey (AIS) Sleep 2011; 34: 997–1011. 16. Zammit GK, Corser B, Doghramji K, et al. Sleep and re‑ sidual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle‑of‑the‑night awa‑ kening. J Clin Sleep Med 2006; 2: 417–423. 17. Lunesta (eszopiclone tablets) prescribing informati‑ on. Marlborough, Massachusetts: Sunovion Pharmaceu‑ ticals Inc.; 2014. Dostupné na: http://www.lunesta.com/ PostedApprovedLabeling‑Text.pdf 18. Krystal AD, Huang H, Zummo J, et al. A WASO sub‑group analysis of a 6-month study of eszopiclone 3 mg. Sleep Med 2012; 13: 691–696. 19. Rozerem (ramelteon tablets) prescribing information. Deerfield, Illinois: Takeda Pharmaceuticals America Inc.; 2010. Dostupné na: http://general.takedapharm.com/content/file. aspx?filetypecode=rozerempi & cacheRandomizer=15ac1d‑ c2-362c-4f72-b98a-5a334d7a2545 20. Almeida Montes LG, Ontiveros Uribe MP, Cortés Sotres J, et al. Treatment of primary insomnia with melatonin: a double‑blind, placebo‑controlled, crossover study. J Psychi‑ atry Neurosci 2003; 28: 191–196. 21. Roth T, Rogowski R, Hull S, et al. Efficacy and safety of do‑ xepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep. 2007; 30: 1555–1561. 22. Silenor (doxepin tablets) prescribing information. Morris‑ town, New Jersey: Pernix Therapeutics; 2010. Dostupné na: https://www.silenor.com/Content/pdf/prescribing‑information.pdf 23. Yeung WF, Chung KF, Yung KP, Ng TH. Doxepin for in‑ somnia: a systematic review of randomized placebo‑controlled trials. Sleep Med Rev 2015; 19: 75–83. 24. Food and Drug Administration FDA approves new type of sleep drug, Belsomra. Dostupné na: http://www. fda.gov/newsevents/newsroom/pressannouncements/ ucm409950.htm 25. Belsomra (suvorexant tablets) prescribing information. White‑house Station, New Jersey: Merck & Co., Inc. Dostup‑ né na: https://www.merck.com/product/usa/pi_circulars/b/ belsomra/belsomra_pi.pdf